NCT00101075View on ClinicalTrials.gov

Title XELOX FOR SALIVARY GLAND CANCERS

PHASE2TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2008

Conditions

Head and Neck Cancer

Interventions

DRUG

Capecitabine

DRUG

Oxaliplatin

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Sanofi-Synthelabo

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Sanofi-Synthelabo

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER